Evidence map›Paper›PMID 36668850›Full record

ArticleToxins2022

Real-Time Documentation of the Effect of Onabotulinumtoxin A Detrusor Injection in OAB Patients-Preliminary Results.

Heinrich Schulte-Baukloh, Catarina Weiß, Sarah Weinberger, Mandy Hubatsch, Thorsten Schlomm, Bernhard Ralla

Open access · goldAbstract read
In one paragraph

Article in Toxins, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Introduction to theToxins · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Heinrich Schulte-BauklohDepartment of Urology, Charité Universitätsmedizin Berlin, 10117 Berlin, Germany.
Catarina WeißUrologic Practice, Kurfürstendamm 139, 10711 Berlin, Germany.
Sarah WeinbergerDepartment of Urology, Charité Universitätsmedizin Berlin, 10117 Berlin, Germany.
Mandy HubatschDepartment of Urology, Charité Universitätsmedizin Berlin, 10117 Berlin, Germany.
Thorsten SchlommDepartment of Urology, Charité Universitätsmedizin Berlin, 10117 Berlin, Germany.
Bernhard RallaDepartment of Urology, Charité Universitätsmedizin Berlin, 10117 Berlin, Germany.
Charité - Universitätsmedizin Berlin · DEMVZ - Kurfürstendamm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Detrusor injection with onabotulinumtoxin A (OnabotA-DI) is an established therapy for overactive bladder (OAB). Little is known about the exact onset and course of the effect in the days after the injection therapy. By using a new type of app-controlled automated diary pod, for the first time, the precise onset of the effect of OnabotA-DI can be documented in real time. Materials and methods: Patients due for OnabotA-DI were asked to document voiding 3 days before and up to 3 weeks after therapy using the Diary Pod app. The detrusor injection was performed with onabotulinumtoxin A (Botox®), 100 units, at 20 sites of the detrusor muscle in a standardized manner. Voiding on the injection day itself was not documented. Results: A total of 17 patients (15 women, 2 men; aged 33−83 (mean 64.6; median 70) years) were included in the study. The handling of the Diary Pod app was user-friendly, and elderly patients did not encounter technical problems. The results of patients with reliably documented micturitions showed a continuous reduction in micturition frequency every day from the first day and significantly from day 5. For 24 h voiding, from 12.83 ± 5.54 in the 3 days before injection, the following mean values were found with significant (p < 0.05) changes after the intervention: 9.17 ± 3.19 on day 5, 8.75 ± 3.69 on day 10, 7.17 ± 2.04 on day 15, and 5.75 ± 0.5 on day 20. These changes were in similar proportions during the daytime and nighttime. Conclusions: Contrary to previous knowledge, the effect of the OnabotA-DI set in from the first postoperative days and was reflected a similar extent in day and night micturition. This study is the first to document the onset of action of OnabotA-DI in real time.

Indexed as

Botulinum Toxins, Type ANeuromuscular AgentsUrinary Bladder, OveractiveAgedFemaleHumansInjectionsMaleMusclesUrinationUrodynamicsBotulinum Toxins, Type ANeuromuscular Agentsbotulinum toxininjectionsintramuscularoveractive bladderurinary bladderurinary incontinence

Identifiers

PMID36668850
PMCPMC9863158
OpenAlexW4313471395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.